STORMS microbiome reporting checklist. حسب Katrine Carlsen (5477300)

الموضوعات:

Overview of the WeARTolerance program. حسب Ana Beato (20489933)

الموضوعات:

Decreasing oxygen saturation with corresponding levels of NLR and D-dimer for understanding the interplay of inflammation. حسب Narendran Gopalan (110148)

Study-related adverse events. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study flow chart. حسب Benjamin R. Lewis (22279166)

الموضوعات:

Study CONSORT diagram. حسب Benjamin R. Lewis (22279166)

الموضوعات:

iKIR score decreases protection associated with protective class II genotypes in T1D. حسب Laura Mora-Bitria (20477525)

Study selection criteria. حسب Filip Stanicic (17808254)

"…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …"

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

"…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …"

PRISMA flow chart. حسب Filip Stanicic (17808254)

"…Phase II/III trials consistently reported significantly greater CAPS improvement with MDMA-AT vs. placebo with therapy (PT) after two or three interventional sessions. …"

Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. حسب William C. Barley (8915282)

الموضوعات:

Regression estimates and incidence rate ratios from GLMER for number of papers (top) and coauthors (bottom). حسب William C. Barley (8915282)

الموضوعات:

This is the data set that we used to reach the conclusions drawn in the manuscript with related metadata and methods. حسب Farayi Kaseke (19560197)

Negative ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). حسب Peng-fei Han (694841)

Positive ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). حسب Peng-fei Han (694841)

Image 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Image 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.jpeg حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"

Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx حسب David Qixiang Chen (8198265)

"…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …"